STAT+: Life science investors close nearly $6 billion in new funds
Biotech and life sciences investors continue to draw in new funds even as the biotech…
Category: STAT+
STAT+: Venture capitalists want to own hospitals. Can they do better than private equity?
General Catalyst’s plan to take over a hospital in the coming months could be the…
STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug
As Medicare prepares to negotiate prices for its first batch of medicines, an advocacy group…
STAT+: DeepMind touts AlphaFold’s new skills as protein-folding AI models face off
On Tuesday, Google DeepMind and Isomorphic Labs announced a significant progress update on the next…
STAT+: White House AI order calls for crackdown on abuses, harms in health care
President Biden’s executive order on artificial intelligence amounts to a giant course correction in health…
STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Eli Lilly to pay $200 million for Beam’s share of drugs from gene-editing firm Verve
Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics…
STAT+: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease
The Food and Drug Administration is convening a meeting of outside experts on Tuesday to…
STAT+: Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial
Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to…
STAT+: Cassava pulled back the curtain on its Alzheimer’s study — and revealed insurmountable problems
Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of…
STAT+: Pharmalittle: FDA flags safety concerns with CRISPR-based sickle cell treatment; FDA warns about eye drop infection risk
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Virtual care options flood the market as retailers take telehealth mainstream
When patients go shopping today, they might find themselves checking out with more than the…
STAT+: What to know about Sarepta’s upcoming data on its Duchenne gene therapy
In the next few weeks, Sarepta Therapeutics will release new data that could change the…
STAT+: Colorado pioneered legal marijuana without sparking ‘reefer madness,’ but challenges lie ahead
DENVER — On Jan. 1, it will be 10 years since customers lined up in…
STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio
It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO…
STAT+: For hospitals after No Surprises Act, physician subsidies are ‘the new contract labor’
Physician staffing firms, flailing in the wake of a federal law banning surprise bills, are…
Senate committee plans Nov. 8 vote on wide-ranging health care package
WASHINGTON — The Senate Finance Committee plans to vote Nov. 8 on legislation that includes…
STAT+: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show
The Food and Drug Administration said on Friday that it has some safety concerns about…
STAT+: Why Sanofi got shellacked
Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion…
STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer
And so, another working week will soon draw to a close. Not a moment too…
STAT+: In major test for prime editing, scientists succesfully correct mutations in monkeys
Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called…
STAT+: ARPA-H head Renee Wegrzyn on the agency’s new Cambridge hub and plans for cancer research
CAMBRIDGE, MASS. — In an area long known as an epicenter of innovation and investment…
STAT+: FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation
The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a…
STAT+: ITC recommends partial import ban of Apple watches in Masimo patent case
The United States International Trade Commission issued a partial import ban of Apple watches on…
STAT+: ALS patients support bill that could help patients with other rare diseases
WASHINGTON — A month after advisers to the Food and Drug Administration overwhelmingly voted against…
STAT+: Teladoc stock slides despite business growth, Medtronic CEO talks innovation
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
STAT+: Pharmalittle: Eisai reports injectable version of Alzheimer’s drug as effective as IV; Pfizer says combo flu and Covid shot shows strong response
Hello, everyone, and how are you this morning? We are doing just fine, thank you,…
STAT+: The health care issue Democrats can’t solve: hospital reform
WASHINGTON — Democrats unilaterally drove major reforms to the health insurance and the pharmaceutical industries…
STAT+: Looking to retain billions, hospitals warn Medicare’s drug payment fix is ‘unlawful’
Hospitals are telling government officials it would be illegal to claw back $7.8 billion as…
STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies,…
STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show
A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler,…
STAT+: Europe takes steps to head off drug shortages, even as U.S. proposals stall
European drug regulators are updating regulations to stem drug shortages. Are there lessons for Americans?…
STAT+: Novartis claims Takeda is stonewalling efforts to review trade secrets taken by a former employee
Novartis has gone to court to gain access to Takeda Pharmaceutical documents over concerns that…
STAT+: Boston Scientific’s drug-coated balloon may reduce risk of heart attack
A drug-coated balloon made by Boston Scientific reduced the risk of heart attack in patients…
STAT+: Biogen’s tau-lowering drug slows cognitive decline in early study of Alzheimer’s disease
An experimental treatment for Alzheimer’s disease that removes a toxic protein called tau from brain…
STAT+: Pharmalittle: Pharma likely to expand legal attacks on Medicare negotiations; CDC recommends rationing RSV drug
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Medtronic CEO talks latest bets on diabetes, high blood pressure technology
As one of the largest and oldest medical device companies in the world, Medtronic has…
STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments
MADRID — If you had to pinpoint one subject that stood out at this year’s…
STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Startup launches with $245 million for twice yearly asthma treatment
A new biotech has raised $245 million to test a new asthma medication that could…
STAT+: ‘Missed opportunities’: Why a U.K. government plan to disclose financial ties between pharma and docs may fall short
Earlier this month, the U.K. government issued a proposal to gather information and opinions about…
STAT+: For Parkinson’s disease, advances spurred by Apple Watch offer a glimmer of hope
Since the Apple Watch was unveiled in 2014, it has been trumpeted not only as…
STAT+: Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole
Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about…
STAT+: Results on Novartis prostate cancer therapy could expand its use
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic…
STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions
MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs…
.jpg)
STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca
MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson…
STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: FDA clears Verve to begin U.S. study of gene-editing treatment for high cholesterol
Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration…
STAT+: Health tech investors are getting selective. Expect slow growth, consolidation
Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to…
STAT+: UnitedHealth discontinues a controversial brand amid scrutiny of algorithmic care denials
UnitedHealth Group and Optum are getting rid of the name of their tech-driven care management…